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Abstract 
This paper presents, for the first time, community-wide estimation of drug and 
pharmaceuticals consumption in England using wastewater analysis and a large number of 
compounds. Among groups of compounds studied were: stimulants, hallucinogens and their 
metabolites, opioids, morphine derivatives, benzodiazepines, antidepressants and others. 
Obtained results showed the usefulness of wastewater analysis in order to provide estimates 
of local community drug consumption. It is noticeable that where target compounds could be 
compared to NHS prescription statistics, good comparisons were apparent between the two 
sets of data. These compounds include oxycodone, dihydrocodeine, methadone, tramadol, 
temazepam, diazepam. Whereas, discrepancies were observed for propoxyphene, codeine, 
dosulepin and venlafaxine (over-estimations in each case except codeine). Potential reasons 
for discrepancies include: sales of drugs sold without prescription and not included within 
NHS data, abuse of a drug with the compound trafficked through illegal sources, different 
consumption patterns in different areas, direct disposal leading to over estimations when 
using parent compound as the DTR and excretion factors not being representative of the local 
community. It is noticeable that using a metabolite (and not a parent drug) as a biomarker 
leads to higher certainty of obtained estimates. With regards to illicit drugs, consistent and 
logical results were reported. Monitoring of these compounds over a one week period 
highlighted the expected recreational use of many of these drugs (e.g. cocaine and MDMA) 
and the more consistent use of others (e.g. methadone). 
Keywords: wastewater analysis, sewage epidemiology, illicit drugs, pharmaceuticals, 
consumption 
1.1 Introduction 
An innovative method of estimating drug consumption utilising the measuring of drug 
residues in wastewater was initially proposed by Daughton in 2001 (Daughton 2001), 
implemented by Zuccato et al. in 2004 (Zuccato, Chiabrando et al. 2005) and followed by 
others (Bones, Thomas et al. 2007, Huerta-Fontela, Galceran et al. 2008, Banta-Green, Field 
et al. 2009, Kasprzyk-Hordern, Dinsdale et al. 2009, Mari, Politi et al. 2009, van Nuijs, 
Pecceu et al. 2009, Karolak, Nefau et al. 2010, Metcalfe, Tindale et al. 2010, Postigo, de Alda 
et al. 2010, Terzic, Senta et al. 2010, Harman, Reid et al. 2011, Irvine, Kostakis et al. 2011). 
The first European monitoring programme was undertaken in 2010 (Thomas, Bijlsma et al. 
2012).  The specific details of this approach are discussed in three review articles (Postigo, 
Lopez de Ada et al. 2008, Zuccato, Chiabrando et al. 2008, van Nuijs, Castiglioni et al. 2010). 
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The method assumes that drugs, after they are consumed and metabolised in the human body, 
are excreted into the sewage system as parent compounds and metabolites. These residues 
reach the WWTP where the wastewater is sampled before treatment. The metabolic pathways 
of many drugs of abuse are understood, with several metabolites known in many cases. 
Therefore, this approach assumes that the measured residue concentrations present in sewage 
can be correlated with the amount of drug consumed by a population served by a WWTP. 
Obvious parameters required to calculate such usage on this scale include: (a) the 
concentration of suitable target species in wastewater; (b) the flow rate of sewage through the 
WWTP at/across the time of sampling (c) the percentage of drug excreted as the selected drug 
target residue (DTR); and (d) the population served by the WWTP. This approach offers 
significant opportunities to aid in the monitoring of drug usage at a community level, however 
to date this concept has received relatively little validation. This paper presents, for the first 
time, the results of estimation of drug and pharmaceuticals consumption in England using 
wastewater analysis and a large number of compounds. Estimation of uncertainty for this 
study is a subject covered in the sister paper entitled ‘Illicit and pharmaceutical drug 
consumption estimated via wastewater analysis. Part B: Accounting for the multiple sources 
of uncertainty’ by H E Jones, M Hickman, A E Ades, N J Welton, D Baker and B Kasprzyk-
Hordern. 
1.2 Experimental 
1.2.1 Sampling location and collection procedures  
Over a seven-day period in March 2011, wastewater was collected as 24 h-composite samples 
from a WWTP in England. Composite sampling was performed continuously over the week 
(every 30 mins) and directly after inlet treatment, which included coarse screens, grit removal 
and fine screens. This treatment works is supplied with sewage primarily from a combined 
sewer infrastructure (~95 %) as well as a small proportion from separate sewers (remaining 5 
%). Five pumping stations are used to deliver sewage to this WWTP (4 of which operate 
intermittently for 30 min every hour and one which is operated continuously). The population 
served by the WWTPs was 3,400,000 inhabitants and therefore represented the largest of its 
kind in the EU. The measured flow rate of influent wastewater through this WWTP across the 
week was 13,300 ± 2400 L/s and measurements were made every 15 min at the outfall 
channel (with an instrument error of ~8 %). On any typical dry weather day, the flow rate 
normally ranges from 8,000-16,000 L/s and can rise as high as 26,000 L/s during wet weather. 
All samples were collected in amber silanised bottles with Teflon-faced caps and frozen in a -
20 
o
C freezer at the WWTP until collection (Fisher, UK). Samples were subsequently 
transported back to the laboratory in a dark and iced cool box and stored at -20 
o
C until 
analysis. 
1.2.2. Chemicals and materials 
Over sixty analytes were chosen for this study (Table S1). A detailed discussion on compound 
selection is presented in the Supplementary Material section. Among chosen analytes are:  
- stimulants and their metabolites: cocaine, benzoylecgonine, norbenzoylecgonine, 
norcocaine, cocaethylene, anhydroecgonine  methyl ester, ecgonidine, amphetamine, 
methamphetamine, methcathinone, BZP  (benzylpiperazine), TFMPP (1-(3-
trifuoromethylphenyl)piperazine),  
- hallucinogens and their metabolites: MDA   (3,4-methylenedioxyamphetamine), 
MDMA  (3,4-methylenedioxymethamphetamine), MDEA  (3,4-
methylenedioxyethylamphetamine), MBDB  (methylbenzodioxazolylbutanamine), BDB  
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(benzodioxazolylbutanamine), mescaline, LSD  (lysergic acid diethylamide), O-H-LSD  (2-
oxo-3-hydroxy-LSD),  
- opioids, morphine derivatives and their metabolites: heroin, 6-acetylmorphine, 
codeine, norcodeine, oxycodone, oxymorphone, morphine, normorphine, dihydrocodeine, 
buprenorphine, norbuprenorphine, methadone, EDDP  (2-ethylidene-1,5-dimethyl-3,3-
diphenylpyrrolidine), EMDP  (2-ethyl-5-methyl-3,3-diphenylpyrroline), fentanyl, norfentanyl, 
propoxyphene, norpropoxyphene, tramadol, nortramadol,  
- benzodiazepines and their metabolites: temazepam, diazepam, nordiazepam, 
nitrazepam, 7-aminonitrazepam, oxazepam, chlordiazepoxide, 
-  antidepressants and their metabolites: dosulepin, amitriptyline, nortriptyline, 
fluoxetine, norfluoxetine, venlafaxine,  
- dissociative anesthetics and their metabolites: phencyclidine, ketamine, norketamine,  
- other: methaqualone, sildenafil, ephedrine, norephedrine, caffeine, 1,7-
dimethylxanthine, nicotine and continine. 
Surrogate/internal standards were all purchased from LGC (UK), with the exception of 
caffeine-d9 (Sigma-Aldrich, UK). All standards and internal standards were of the highest 
purity available (>97%). Individual stock solutions were purchased or prepared from 
powdered substance in either acetone or methanol at a concentration of 1 or 0.1 g L
−1
 and 
stored in the dark at −20 oC. LC-MS mobile phase solvents and additives were all of LC–MS 
quality and purchased from Sigma–Aldrich (UK) and Fisher (UK). Ultra-pure water used for 
pressurised liquid extraction (PLE) was taken from a Barnstead Nanopure water purification 
system (Thermo Fisher Scientific, UK). 
1.2.3. Analytical methodology 
The analytical methodology was carried out according to the validated protocol described 
elsewhere (Baker and Kasprzyk-Hordern 2011a-c). A brief discussion on methodology and its 
validation is provided in the Supplementary Material section (see Analytical Methodology 
and Tables S2-4). All samples were prepared using solid-phase extraction and PLE (for 
extraction of suspended solids). All analyte determinations were performed using ultra-high 
pressure liquid chromatography coupled with tandem mass spectrometry (using a Waters 
ACQUITY UPLC
TM
-TQD instrument). Liquid chromatography separations were achieved 
with an ACQUITY UPLC BEH C18 (1.7 µm; 1 × 150 mm) column.  
1.2.4. Sewage epidemiology back-calculations 
Measured concentrations (ng L
-1
) of target analytes in wastewater influent were used to back-
calculate drug usage in local areas. Estimations were made for DTRs that were detected in 
wastewater influent and for which the necessary excretion data was available; hence back-
calculations were not possible for all compounds. Estimations were based on an approach first 
described by Zuccato et al. (2005) and subsequently modified in this study. The modifications 
to the calculation represents an attempt to account for the sorption of target analytes to SPM 
and stability of analytes in wastewater; factors which previous authors (Zuccato, Chiabrando 
et al. 2005, Bones, Thomas et al. 2007, Boleda, Galceran et al. 2009, Kasprzyk-Hordern, 
Dinsdale et al. 2009, Postigo, de Alda et al. 2009, Karolak, Nefau et al. 2010, Terzic, Senta et 
al. 2010) assumed negligible due to lack of data. The following description and formulas 
describe the method by which estimates were calculated.  
The concentration (ng L
-1
) of a given DTR was firstly multiplied by the flow rate (L day
-1
) of 
influent. This number was then corrected to account for stability and adsorption to solids, as 
listed in Table 1. Assuming no loss of sewage water along the pipes (none was recorded either 
as a planned overflow or outage during this period), this provided an estimate of the load (g 
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day
-1
) of a selected DTR arriving at a selected treatment plant. The formula used to calculate 
daily loads is shown in Equation 1. The percentage excretion of a target DTR was then taken 
into account (after relevant forms of administration), along with the molar mass ratio between 
the parent drug and the DTR to provide an estimate of the load of parent drug (g day
-1
). The 
load of parent drug was then divided by the number of people served by the WWTP in order 
to equate the load per 1000 people (mg day
-1
 1000 people
-1
). The detection of a DTR in 
wastewater may also be as a result of discharge from other irrelevant sources. In these cases 
the amount should be subtracted from consumption estimates. The formula to calculate mg 
day
-1
 1000 people
-1
 is shown in Equation 2. 
3
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Equation 1 – Load per day calculation 
Where: Concentration corresponds to the DTR concentration (ng L
-1
), Flow to the wastewater 
influent volume over a 24 hour period (m
3
 day
-1
), Stability the stability change of each 
compound (%) after 12 hours and Sorption the sorption (%) of each compound to SPM.   
1 1000
1000 Par
DTR
MW
Consumption Load OS
Excretion MW Population
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Equation 2 – mg day-1 1000 people-1 
Where: Load corresponds to the amount of DTR arriving at the WWTP (g day
-1
); Excretion - 
the percentage excretion of the DTR after relevant forms of administration; MWPar - the 
molecular weight of the parent compound and MWDTR - the molecular weight of the DTR. OS 
refers to the amount of DTR that is present in wastewater due to other sources other than the 
parent compound, if applicable (mg day
-1
 1000 people
-1
). 
1.3. Results and discussion 
The levels of drugs of abuse and metabolites quantified in wastewater and suspended 
particulate matter are summarised in Tables S5 and S6. Corresponding loads (g day
-1
) of 
analytes in wastewater are listed in Table 2.  
1.3.1. Drug consumption at community level (wastewater derived back-calculations) 
Several DTRs were frequently quantified at sometimes relatively high concentrations in both 
wastewater influents and in suspended matter, as presented in Table S5 and 6. These 
concentrations were extrapolated to estimate loads of target analytes and consumption of 
parent drugs in local communities. Estimations were only possible for those DTRs that were 
detected in wastewater and for which excretion data was available that was derived from 
relevant forms of administration.   
1.3.1.1. Common illicit/drugs of abuse 
1.3.1.1.1. Cocaine  
Back-calculations for cocaine use in local communities have been carried out in several ways 
in the literature. The most common method is through the use of benzoylecgonine loads, as 
first proposed by Zuccato et al. (2005) and subsequently followed by several other authors 
(Huerta-Fontela, Galceran et al. 2008, Boleda, Galceran et al. 2009, Postigo, de Alda et al. 
2009, Karolak, Nefau et al. 2010, Terzic, Senta et al. 2010, van Nuijs, Mougel et al. 2011, 
Kinyua and Anderson 2012, Lai, Bruno et al. 2013). In contrast, Bones et al. (2007) employed 
the use of loads of parent compound, cocaine. Benzoylecgonine has been shown to be more 
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stable in wastewater compared to cocaine (Baker and Kasprzyk-Hordern 2011). Secondly, as 
cocaine may be present in wastewater due to direct disposal, the presence of benzoylecgonine 
is more indicative of human consumption. Therefore it was unsurprising that, under such 
circumstances, over-estimations of community consumption were observed using cocaine as a 
DTR in previous work (Kasprzyk-Hordern, Dinsdale et al. 2009). The use of ecgonine methyl 
ester as a DTR was also explored by van Nuijs et al. (2011), but the authors found no 
significant calculated differences to the use of benzoylecgonine in community-wide 
consumption estimates. However, the authors decided to retain use of benzoylecgonine as it 
displayed better stability in wastewater compared to ecgonine methyl ester (Baker and 
Kasprzyk-Hordern 2011). Uncertainties related to cocaine use back-calculation are discussed 
by Castiglioni et al. (Castiglioni, Bijlsma et al. 2013). 
In this study, cocaine consumption estimates based on the measured loads of the metabolite, 
norbenzoylecgonine, are also provided, along with both benzoylecgonine and parent 
compound loads. Average cocaine estimates over the one week sampling period for the three 
DTRs are shown in Table 3. The results show that consumption estimates are significantly 
higher when cocaine is used as a DTR. In this case, usage of cocaine was estimated to be on 
average 9,793 mg day
-1
 1000 people
-1
, while using benzoylecgonine it was estimated to be 
1,263 mg day
-1
 1000 people
-1
. By comparing calculated estimates using norbenzoylecgonine 
and benzoylecgonine as DTRs, similar results were observed (1,368 mg day
-1
 1000 people
-1
). 
Norbenzoylecgonine previously showed good stability in wastewater (Baker and Kasprzyk-
Hordern 2011) and maybe it is a suitable DTR; however, as it is a minor metabolite (excretion 
= 0.95%), errors could be introduced with only slight changes in excretion values. 
Nonetheless, it is worth considering the use of all three metabolites as DTRs 
(benzoylecgonine, norbenzoylecgonine and ecgonine methyl ester), where detected above the 
method quantification limits, and thereby potentially removing the reliance of targeting a 
single analyte. Based on excretion data for cocaine after consumption (excretion of cocaine = 
1.45 %, excretion of benzoylecgonine = 30.07 %) and their molar mass relation, the excreted 
COC/BE ratio should be ~0.05 (with a range from 0.02 to 0.27 according to Postigo et al. 
(Postigo, de Alda et al. 2009). In this work, the average ratio in wastewater influent was 
higher than expected from excretion rates, with an average ratio of 0.42±1.5. This value is 
consistent with the ratios determined in Belgium by van Nuijs et al. (2009) which were 
typically in the range 0.30 – 0.50. This seemingly higher ratio is therefore proposed to be due 
to higher cocaine concentrations. Predicted loads of benzoylecgonine matched up reasonably 
well with experimentally determined loads in the work by Kahn et al. (2011) and back-
calculations using benzoylecgonine compared well with official drug statistics in several 
countries (van Nuijs, Castiglioni et al. 2011, van Nuijs, Castiglioni et al. In press). Several 
potential causes of such varied calculated cocaine concentrations have been/are proposed: 
1. Direct disposal of cocaine into the sewage system (Kasprzyk-Hordern, Dinsdale et al. 
2009, Postigo, de Alda et al. 2009, van Nuijs, Castiglioni et al. In press). However, as the 
COC/BE ratio was high in nearly every sample collected during this study and the study of 41 
treatment plants by Van Nuijs et al. (2009), one would assume constant direct disposal of 
cocaine is unlikely. 
2. An undocumented legal usage of cocaine. NHS prescription data for England (NHS 
2011) has suggested only very negligible amounts are prescribed and therefore, in relation to 
measurements made on this scale, this is also unlikely. 
3. Another potential reason could be due to the excretion of cocaine as the unchanged 
drug in alternative excretion routes (e.g. in sweat). Consequently, unchanged cocaine may 
enter the sewage system due to washing. Currently, however, to the authors knowledge there 
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is no data to establish whether or not significant amounts of cocaine are excreted through this 
route. 
4. Co-administration of cocaine with ethanol may increase the amount of excreted parent 
drug (Khan and Nicell 2011). This is a logical suggestion, but more knowledge is required. 
Cocaethylene, a metabolite formed through co-administration of cocaine and ethanol, was 
detected in increased amounts on weekends during two, one-week monitoring studies; hence 
it can be suggested that co-administration of cocaine and ethanol is far increased during the 
weekend in relation to weekdays. In comparison, analysis of COC/BE ratios during the two 
one-week monitoring studies found little difference in the ratios during weekdays and the 
weekends. 
5. Variation in the metabolic COC/BE ratio may occur before sampling given the 
chemical and microbial complexity of municipal sewage. At the very least, storage stability 
studies indicate that transformation occurs over a relatively short period for cocaine-related 
species (Baker and Kasprzyk-Hordern 2011, González-Mariño, Quintana et al. 2012).  
 
The results obtained indicate that the average usage of cocaine in the area studied was 
estimated to be 1,263 mg day
-1
 1000 people
-1 
(Table 3, based on benzoylecgonine loads). The 
results of this study are in accordance with data obtained by others (Zuccato, Chiabrando et 
al. 2005, Bones, Thomas et al. 2007, Huerta-Fontela, Galceran et al. 2008, Zuccato, 
Chiabrando et al. 2008, Boleda, Galceran et al. 2009, Kasprzyk-Hordern, Dinsdale et al. 2009, 
Postigo, de Alda et al. 2009, van Nuijs, Pecceu et al. 2009, Karolak, Nefau et al. 2010, Terzic, 
Senta et al. 2010, van Nuijs, Mougel et al. 2011). The daily results of the one week 
monitoring study showed that increased amounts of cocaine were consumed during the 
weekend. Table 2 shows the daily loads of cocaine DTRs (parent compound, 
benzoylecgonine, cocaethylene and norbenzoylecgonine), with an increase in the loads of all 
four DTRs. This increase was especially apparent for cocaethylene, when compared to 
benzoylecgonine, on the weekend compared to weekdays. This finding would suggest that co-
administration of cocaine and ethanol is far more pronounced during the weekend as opposed 
to weekdays. This weekend or recreational use of cocaine is consistent with official 
EMCDDA reports (EMCDDA 2009), and wastewater analysis in both Belgium (van Nuijs, 
Mougel et al. 2011) and Croatia (Terzic, Senta et al. 2010).  
1.3.1.2. Amphetamine 
Determination of amphetamine consumption has widely utilised the parent compound as the 
DTR (Zuccato, Chiabrando et al. 2008, Kasprzyk-Hordern, Dinsdale et al. 2009, Postigo, de 
Alda et al. 2009, Terzic, Senta et al. 2010, van Nuijs, Mougel et al. 2011). The results of 
back-calculations for these studies are listed in Table 3. In this study, the average 
consumption was 86 mg day
-1
 1000 people
-1
. These results compare well with reported results 
in Belgium (van Nuijs, Mougel et al. 2011), Croatia (Terzic, Senta et al. 2010), Italy and 
England (London) (Zuccato, Chiabrando et al. 2008).  
The contribution of legal consumption of amphetamine in sewage, including the occurrence 
of their associated excreted metabolites of selegiline and methamphetamine (refer to 
Supplementary Material), makes the estimation of illicit amphetamine usage challenging. In 
England in 2010, 14.1 kg of selegiline and 23.8 kg of amphetamine were prescribed, with a 
dose of selegiline excreted mainly as methamphetamine and amphetamine (excretion rates 
have not been reported for selegiline to the author’s knowledge). In relation to consumption 
estimates for England, prescribed values are negligible; accounting for approximately 1 mg 
day
-1
 1000 people
-1
 (assuming a dose of selegiline is excreted as 50 % amphetamine).  
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Amphetamine is a recreational drug that is often associated with ‘nightclub’ culture 
(EMCDDA 2009). This was seemingly confirmed through daily monitoring of amphetamine 
levels in Croatia by Terzic et al. (2010), with higher amphetamine loads reported during the 
weekend in comparison to weekdays. However, no increase in amphetamine use was 
observed here during the weekend. Reasons for this could be that usage of amphetamine 
follows a different pattern in England and legal usage throughout the week is significant. 
More importantly, it must be remembered that the presence of amphetamine in wastewater 
was not confirmed, hence an unknown compound could have potentially been quantified with 
amphetamine and resulted in an overestimation of values (see papers by Baker and Kasprzyk-
Hordern for further discussion (Kasprzyk-Hordern, Kondakal et al. 2010, Baker and 
Kasprzyk-Hordern 2011, Baker and Kasprzyk-Hordern 2011)). For this reason, further 
investigation into the analytical problems surrounding amphetamine analysis is required. 
Chiral analysis of enantiomers of amphetamine should be also undertaken to help with 
differentiating between direct disposal, consumption, and legal and illicit use (Kasprzyk-
Hordern and Baker 2012). 
1.3.1.3. Methamphetamine 
The average consumption of methamphetamine was determined to be 17 mg day
-1
 1000 
people
-1
. The results of this study are higher from those of Postigo et al. (2009) in which 
methamphetamine was detected in only 14 % of samples, with an average consumption of 1.5 
mg day
-1
 1000 people
-1 
aged 15-34 and the results of van Nuijs et al. (2011) in which an 
average consumption of 2 mg day
-1
 1000 people
-1 
was determined.  
Consumption estimates for methamphetamine are consistent with official Home Office data 
which suggests that abuse of methamphetamine is low with only 0.1 % of those aged 16 – 59 
years having taken the drug in the last year in England and Wales; with usage of 
methamphetamine also typically low for most European countries (EMCDDA 2009). The 
weekly monitoring campaign indicated an increase in weekend use (Table 3). 
1.3.1.4. MDMA 
The mean consumption of MDMA was 148 mg day
-1
 1000 people
-1
, see Table 3. The average 
consumption determined in this study is higher than the reports of 13 and 3.6 mg day
-1
 1000 
people
-1 
in Belgium and Croatia (Terzic, Senta et al. 2010, van Nuijs, Mougel et al. 2011), 
while the results of the study are generally consistent with the 200 mg day
-1
 1000 people
-1 
reported in Spain (Huerta-Fontela, Galceran et al. 2008). 
Table 3 presents the determined consumption in over the week long monitoring campaign. 
The results show that levels of MDMA increase substantially during the weekend, which is 
consistent with reports of MDMA use as a ‘club’ drug (EMCDDA 2009). The increase in 
levels at the weekend are also similar to the results of wastewater analysis reported in 
Belgium (van Nuijs, Mougel et al. 2011) and Croatia (Terzic, Senta et al. 2010).  
1.3.1.5. Heroin 
In previously reported studies, estimates for heroin consumption have employed either 
morphine (Zuccato, Chiabrando et al. 2008, Boleda, Galceran et al. 2009, Postigo, de Alda et 
al. 2009, Terzic, Senta et al. 2010) or 6-acetylmorphine (van Nuijs, Mougel et al. 2011) as 
DTRs. However in the authors’ opinion, neither DTR is suitable to estimate heroin usage.  
Morphine has several legal sources, which includes morphine itself, codeine, ethylmorphine, 
nicomorphine, pholcodine (Baselt 2008).  In previously published literature, authors have 
subtracted estimated loads of morphine resulting from legal use of morphine itself, and then 
used the remaining amount of morphine to estimate heroin consumption, as first reported by 
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Zucatto et al. (2008). However, in England, the amount of morphine and codeine distributed 
is significant. In England in 2010, 3993 kg of morphine and 37117 kg of codeine were 
distributed (NHS 2011). Assuming a dose of morphine is excreted as 77 % parent compound 
and a dose of codeine is excreted as 6.0 % morphine (see Supplementary Material) this results 
in a total yearly amount of morphine excreted (3075 kg + 2227 kg) of 5301 kg, or 442 kg per 
month (assuming of course that all medication is consumed rather than directly disposed and 
that an equal amount of medication is used in each month throughout the year).  In England 
and Wales in 2010, a reported 0.04 % of people aged 16-59 used heroin in the last month 
(Home Office 2011). Thus, applying this usage statistic to the population of England aged 16-
59 (30,721,241 people aged 16-59, (ONS 2010)), gives a total 12,288 users a month 
(assuming one dose per person a month). A typical daily dose of heroin at street purity is 100 
mg (EMCDDA 2010) or 30 mg (INCB 2008, UNODC 2008). Hence, if 12,288 users consume 
the reported average daily dose (using a midpoint of 65 mg), this results in a monthly heroin 
consumption of 0.80 kg. Taking into account that a heroin dose is excreted as 55 % morphine 
gives a total of 0.44 kg of morphine a month related to heroin usage. Comparing this figure of 
0.44 kg illicit morphine to that of 442 kg legal morphine, shows that only 0.01 % of morphine 
in wastewater is related to illegal usage. This is of course an approximate value based on 
several mentioned assumptions; nevertheless it provides evidence for that fact that morphine 
is a completely unsuitable DTR - in England at least. This finding is likely to be true for 
several other countries where morphine and codeine usage is relatively high in relation to 
heroin usage. Furthermore, whilst the measured component sorbed to solids was 0.9 % here, 
previous works have shown that transformation or degradation of morphine is likely in semi-
solid suspensions and which may therefore result in an under-estimation of morphine 
concentration after a very short residence time (Barron, Havel et al. 2009). In this reported 
work, the liquid-phase concentration diminished rapidly within 24 h (<10 % after 12 h) and 
the measured sorbed component also remained low (as here) leading to a mass imbalance.  
The alternative DTR to monitor heroin is the minor metabolite 6-acetylmorphine. To date, 
only van Nuijs et al. (2011) have based back-calculations on this compound. A major 
advantage of this DTR is that there are no significant additional sources as with morphine. On 
the other hand, 6-acetylmorphine is a minor metabolite of heroin (Khan and Nicell 2011), 
hence analytical detection limits need to be low and correction factors for back-calculations 
are high, meaning high uncertainties could be introduced. However the main problem with the 
usage of 6-acetylmorphine at present is the lack of relevant excretion data. In the study by van 
Nuijs et al. (2011) an excretion rate of 1.3 % was used. This value of 1.3 % is based on data 
generated by irrelevant prolonged infusion (Elliott, Parker et al. 1971); hence the excretion 
rate is likely to be different for relevant forms of administration such as chasing (excretion of 
heroin is covered in more detail in Supplementary Material). For this reason, until excretion 
data is published for relevant forms of administration, in the authors’ opinion, back-
calculations are not appropriate. As 6-acetylmorphine is relatively unique to heroin, it could 
be nevertheless a suitable target residue to monitor WWTP loads.  
1.3.1.6. Methadone 
In England, methadone is administered to patients under supervised conditions for at least 
three months and until they are deemed ‘stable’ (NHS 2009, NHS 2010). The controlled 
nature under which methadone is administered makes it a suitable compound to monitor in the 
environment as direct disposal or administration by other means is unlikely due to the 
supervision of medical staff during administration in the UK. Furthermore, prescription 
records for methadone are readily available. 
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During the monitoring study, three excreted products for methadone were analysed (parent 
compound, EDDP and EMDP). As direct disposal is unlikely in the case of methadone, parent 
compound itself is a suitable DTR in addition to the metabolites. Back-calculations using the 
three DTRs are listed in Table 3. Average consumption of methadone using parent compound 
as the DTR was determined to be 84 mg day
-1
 1000 people
-1
, which is slightly lower than that 
determined using EDDP as the DTR of 113 mg day
-1
 1000 people
-1
. NHS prescription data for 
methadone in England in 2010 reported that 1856 kg of the free base was prescribed; the 
equivalent of 97 mg day
-1
 1000 people
-1
.  
The average consumption estimate of this study (113 mg day
-1
 1000 people
-1
) is marginally 
lower than the average 138 mg day
-1
 1000 people
-1
 estimated in Belgium (van Nuijs, Mougel 
et al. 2011) and 148 mg day
-1
 1000 people
-1
 estimated in Croatia (Terzic, Senta et al. 2010). In 
both of the previous studies EDDP was used as the DTR; back-calculations using parent 
compound as the DTR were not reported.  
Mass loads during daily, one week monitoring studies presented no pattern of usage, with 
loads of EDDP and methadone relatively consistent throughout the week, see Table 2. This is 
a logical observation since, as previously mentioned, methadone is administered under the 
supervision of medical staff.  
1.3.1.7. TFMPP and BZP 
Consumption estimates for TFMPP and BZP are not possible due to the lack of human 
elimination data for these compounds, see Supplementary Material. Nevertheless, it is 
possible to monitor the loads of these compounds at a WWTP to assess whether or not any 
patterns are visible. Mass loads during one week monitoring studies indicated low use of both 
TFMPP and BZP. This finding is consistent with reports of TFMPP use on the ‘club’ or ‘rave’ 
scenes (U.S. DEA 2003).  
1.3.1.8. Ketamine 
Ketamine use in England and Wales has doubled over the last four years (Home Office 2011). 
Back-calculations for ketamine are not possible for two reasons. Firstly there are no data, to 
the author’s knowledge, relating to the percentage of elimination of each metabolite after a 
dose of ketamine is consumed through insufflation; the primary route of administration (Wills 
2005). Ketamine may also be consumed orally (Moore, Sklerov et al. 2001, Kim, Lee et al. 
2008, Parkin, Turfus et al. 2008) and intravenously (Wieber, Gugler et al. 1975, Adamowicz 
and Kala 2005). Secondly ketamine is used as a veterinary drug, for which there is no 
distribution data, hence veterinary use cannot be distinguished from human use. Although 
back-calculations cannot be reliably attempted it is possible to monitor loads of ketamine over 
an extended period. 
Loads of ketamine during daily, one week monitoring studies are presented in Table 2. As 
ketamine is regarded as a ‘club’ drug (Sproule 2006) it was expected to see an increase of 
loads due to human usage at the weekend; this was not observed.  
1.3.2. Prescription/over-the-counter drugs of abuse 
The method discussed here can be applied to almost any other chemical with an understood 
fate and route of disposal. Therefore the consumption of prescription/over-the-counter drugs 
was also verified using the above approach. Obtained values from wastewater analysis were 
compared with prescription data by the NHS (NHS 2011), and where possible with estimated 
over-the-counter sales. NHS prescription data covers prescriptions dispensed in the 
community, i.e. community pharmacists, dispensing doctors, and items personally 
administrated by doctors and also dentists and hospital doctors. The data does not include 
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items dispensed in hospitals or on private medications. A comparison between wastewater 
estimates in this current study and NHS data is presented in Table 4. 
1.3.2.1. Codeine 
In England in 2010, 31925 kg of codeine free base were prescribed (NHS 2011), in addition 
to an estimated 5192 kg over-the-counter sales (see Supplementary Material). This 
distribution data corresponds to an estimated 1946 mg day
-1
 1000 people
-1
. During wastewater 
analysis, both codeine and norcodeine were determined. Consumption estimates based on 
parent compound as a DTR were on average 565 mg/day/1000 people, and based on 
norcodeine as a DTR estimates were on average 225 mg day
-1
 1000 people
-1
, see Table 4. 
Therefore, wastewater consumption estimates were someway short of the estimate based on 
NHS data. There are many potential reasons for underestimation between NHS data and 
wastewater data. For instance, the excretion data used to carry out back-calculations may not 
have been representative of the local population resulting in under-reporting or not all 
prescribed codeine was consumed/disposed of. Similarly, as codeine also metabolises to 
morphine, similar transformation effects may occur as discussed above. 
1.3.2.2. Tramadol 
Results based on wastewater analysis with NHS prescription data compared well in this case. 
Based on NHS data, consumption of tramadol in 2010 in England was 1654 mg day
-1
 1000 
people
-1
. Wastewater analysis using tramadol as the DTR was on average 1067 mg day
-1
 1000 
people
-1
, while using the metabolite nortramadol as the DTR provided similar estimate of 948 
mg day
-1
 1000 people
-1
, see Table 4. Combined with this, sorption of tramadol to solids is 
generally expected to be low and this was confirmed again here  (Barron, Havel et al. 2009). 
Relative variance using the parent compound is likely to be low in comparison to some other 
species studied here given its % excretion at 31.9 %. 
1.3.2.3. Dihydrocodeine and oxycodone 
Results based on wastewater analysis compared to NHS data for both dihydrocodeine and 
oxycodone were in good agreement, see Table 4. The consumption estimate for 
dihydrocodeine based on NHS data was 225 mg day
-1
 1000 people
-1 
and the estimate 
determined through wastewater analysis was, on average, 244 mg day
-1
 1000 people
-1 
in this 
study.  
Based on NHS data, consumption of oxycodone was approximately 54 mg day
-1
 1000 people
-
1
. This is consistent with the wastewater figure of 20 mg day
-1
 1000 people
-1 
estimated when 
using parent compound as the DTR. The estimate when using oxymorphone as the DTR was 
slightly higher at 29 mg day
-1
 1000 people
-1
. Results obtained when using oxycodone and 
oxymorphone as DTRs is shown in Table 4. 
1.3.2.4. Propoxyphene 
Back-calculations for propoxyphene were based solely on the metabolite norpropoxyphene, as 
parent compound was rarely detected in wastewater influent samples (please see the 
Supplementary Material Section for method detection/quantification limits). Based on 
norpropoxyphene as the DTR, consumption of propoxyphene was on average 249 mg day
-1
 
1000 people
-1
. This is roughly 5 times higher than that estimated based on NHS data of 47 mg 
day
-1
 1000 people
-1
. Over-estimation of drug usage may be a result of several factors such as: 
distribution of drug that has not been recorded in NHS data, different consumption patterns in 
local areas and excretion rates used in back-calculations may not have been representative of 
the local population. 
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1.3.2.5. Temazepam and diazepam 
Back-calculations of diazepam were estimated using oxazepam as a DTR. Back calculations 
using the parent compound were not possible as diazepam was not detected in analysed 
samples (please see the Supplementary Material Section for method detection/quantification 
limits) and the percentage excretion of nordiazepam has not been accurately reported and so 
cannot be used. As discussed in the Supplementary Material, however, oxazepam is also a 
drug itself and is almost entirely excreted as the parent (or the conjugate) with 94.5 kg of the 
free base prescribed in 2010 (the equivalent of 1.81 mg day
-1
 1000 people
-1
). Oxazepam is 
also a metabolite of temazepam, although it is a relatively minor metabolite and hence will be 
considered negligible for back-calculation purposes. Back-calculations of diazepam using 
oxazepam as the DTR, minus prescribed oxazepam, resulted in an average estimate of 28 mg 
day
-1
 1000 people
-1 
which is in good agreement with the estimate of 37 mg day
-1
 1000 people
-
1 
based on NHS prescription data. 
Temazepam is predominately excreted as parent compound and conjugated parent compound, 
hence temazepam itself was utilised as the DTR. Back calculations for temazepam resulted in 
an average consumption estimate of 75 mg day
-1
 1000 people
-1
, which compares relatively 
well with the estimate of 54 mg day
-1
 1000 people
-1 
based on NHS prescription data.  
1.3.2.6. Dosulepin 
Consumption estimates using the parent compound as a DTR in wastewater resulted in an 
estimate of 111 mg day
-1
 1000 people
-1
, which correlates with the estimate based on NHS data 
of 191 mg day
-1
 1000 people
-1
 (Table 4).  
1.3.2.7. Amitriptyline 
Based on NHS prescription data on average 419 mg day
-1
 1000 people
-1 
of amitriptyline is 
consumed per year. The value of 101 mg day
-1
 1000 people
-1 
estimated when nortriptyline 
was used as a DTR is lower than the NHS estimate. However when the parent compound was 
used as the DTR, a seemingly inflated figure of 2154 mg day
-1
 1000 people
-1 
was estimated. 
Over-estimation based on using the parent compound as a DTR is likely a result of the very 
low excretion factor (2 %) used in the back-calculation. Hence, as the excretion factor is low, 
if the excretion percentage in reality deviates significantly from this then it will have a major 
impact of the result. Furthermore, it should be noted that sorption of amitriptyline, fluoxetine 
and dosulepin-related compounds are expected to be high given their relative logP/logD and 
this was apparent here also. In particular, nortriptyline and amitriptyline have been shown to 
sorb heavily to sewage sludges at 600-1049 L/kg respectively (Barron, Havel et al. 2009). 
Some sorption in sewage prior to sampling is also likely to occur and could account for the 
variable estimates here.  
1.3.2.8. Fluoxetine 
Consumption estimates for fluoxetine were relatively similar at all WWTPs when using both 
parent compound and norfluoxetine as DTRs, see Table 4. Based on NHS prescription data a 
consumption estimate of 226 mg day
-1
 1000 people
-1 
people is derived, which compares well 
with the estimate of 98 mg day
-1
 1000 people
-1 
people using parent compound as a DTR and 
54 mg day
-1
 1000 people
-1
 using norfluoxetine as a DTR. Again, lower estimates could arise 
from sorption to suspended solids prior to sampling. It is clear, that further work is required 
on these compounds if the back-calculation approach is to be extended to over-the-counter 
drugs. 
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1.3.2.9. Venlafaxine 
Consumption estimates for venlafaxine based on using the parent compound as a DTR 
showed a large over estimation in comparison to NHS data. NHS prescription data shows that 
approximately  417 mg day
-1
 1000 people
-1 
is consumed, which is far lower than the 1276 mg 
day
-1
 1000 people
-1 
estimated through using parent compound as the DTR. Sorption of 
venlafaxine was low here, and consistent with other studies with sludge interaction (Hörsing, 
Ledin et al. 2011). However, data from stability during storage (up to 20 % reduction after 12 
h) indicate that some losses are likely before the sampling point (Baker and Kasprzyk-
Hordern 2011). A more appropriate DTR is likely to be the main metabolite O-
desmethylvenlafaxine.  
1.3.2.10. Other compounds 
Caffeine loads remained stable during the monitoring week. Consumption estimated for 
caffeine based on using the parent compound as a DTR were significantly overestimated (742 
g day
-1
 1000 people
-1
) when compared with consumption estimated obtained for DTR 1,7-
dimethylxantine (190 g day
-1
 1000 people
-1
) (Table 3). Nicotine loads remained, as expected, 
constant throughout sampling week and denoted on average 0.91 g day
-1
 (Table 2). Nicotine 
consumption could not be estimated as its metabolic DTR could not be quantified in 
wastewater. Sildenafil’s daily mass loads were observed to increase during weekends possibly 
due to its abuse potential; however its consumption could not be estimated due to lack of 
metabolic DTR. 
Caffeine, nicotine as well as prescription pharmaceuticals such as antidepressants could be 
used to estimate population size served by studied wastewater treatment plant. Such an 
investigation will be subject to further research. 
2. Conclusions and future outlook 
The above results show the usefulness of wastewater analysis in order to provide estimates of 
local community drug consumption. It is noticeable that where target compounds could be 
compared to NHS prescription statistics, good comparisons were apparent between the two 
sets of data. These compounds include oxycodone, dihydrocodeine, methadone, tramadol, 
temazepam, diazepam. Whereas, discrepancies were observed for propoxyphene, codeine, 
dosulepin and venlafaxine (over-estimations in each case except codeine). Potential reasons 
for discrepancies were discussed above for each compound, but in general, these factors 
include: sales of drugs sold without prescription and not included within NHS data, abuse of a 
drug with the compound trafficked through illegal sources, different consumption patterns in 
different areas, direct disposal leading to over estimations when using parent compound as the 
DTR and excretion factors not being representative of the local community. It is noticeable 
that using a metabolite (and not a parent drug) as a biomarker leads to higher certainty of 
obtained estimates. With regards to illicit drugs, consistent and logical results were reported. 
Monitoring of these compounds over a one week period highlighted the expected recreational 
use of many of these drugs (e.g. cocaine and MDMA) and the more consistent use of others 
(e.g. methadone). 
The sewage epidemiology approach has a number of advantages in comparison to current 
methods of estimation, such as population surveys, crime statistics and hospital admissions. 
Wastewater analysis provides near-real time data, with sample collection, analysis and data 
reporting achieved in around 24 hours (depending on the time of sample collection). This 
would allow relevant authorities to rapidly identify emerging hotspots of drug abuse and also 
assess the effectiveness of counter measure tactics. The analysis of wastewater may provide a 
more reliable estimation of drug usage; as data is generated from a direct source rather than 
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indirect sources such as population surveys in which participants may (for example) be 
untruthful about their drug habits.  
Knowledge of the excretion of a DTR after consumption plays a crucial role in back-
calculations of drug consumption. However the majority of published data has many flaws for 
utilisation in sewage epidemiology back-calculations. For instance, the majority of data is 
rather old (typically early 1980’s), and is based on a limited number of subjects. Furthermore, 
the administration method in some cases is not relevant to the manner in which the drug is 
consumed nowadays and the dosage size administered is often far smaller. Typically, large 
deviations are reported in the excretion percentages of a DTR, such as MDMA, which has a 
reported excretion ranging from 5.9 to 47.7 % (Khan and Nicell 2011). To improve 
knowledge of the excretion of a DTR, a comprehensive literature search should be carried out. 
This is a difficult process, given the lack of publications and the age of the publications 
making retrieval of information problematic. In order to unambiguously define excretion of 
selected drugs of abuse, new more comprehensive pharmacokinetic studies should be carried 
out that resolve issues surroundings number of subjects, administration, dosage size and with 
analysis of urine, faeces and sweat of subjects. Pharmacokinetic studies, however, are not a 
straightforward affair; hence a significant amount of time and funding will be required to 
accomplish this goal. 
Back-calculations are also subject to two other important parameters; the number of 
inhabitants served by the WWTP and the flow rate. The number of inhabitants served by a 
WWTP is constantly changing due to factors such as commuting and holidays. Typically, 
local population census information or WWTP design capacity is used to estimate population. 
An alternative method could be to determine biological oxygen demand (BOD), chemical 
oxygen demand (COD), total phosphorous (P) and nitrogen (N) in wastewater. These 
measurements may enable the indication of population (Zessner and Lindtner 2005, Garnier, 
Laroche et al. 2006), with recent application for the first time with regards to drugs of abuse 
by van Nuijs and co-workers (2011). Although BOD, COD, N and P may help indicate 
population, they are not ideal, as measurements require another analytical method. Ideally, a 
human indicator present in samples that may be analysed along with the targeted drugs of 
abuse would allow significant efficiencies as one method would be required for analysis. 
Among such compounds may be: creatinine, metabolites of caffeine, nicotine or prescription 
medications. With regards to the flow rate, over or under-estimation can have a significant 
impact on calculated loads. To minimise the error from this variable, relevant WWTP 
personnel should be contacted. It is likely that error with regards to flow rate measurements 
will be ‘low’ in modern WWTPs (Zuccato, Chiabrando et al. 2008). 
Estimation of uncertainty for this study is a subject covered in the sister paper entitled ‘Illicit 
and pharmaceutical drug consumption estimated via wastewater analysis. Part B: Accounting 
for the multiple sources of uncertainty’ by H E Jones, M Hickman, A E Ades, N J Welton, D 
Baker and B Kasprzyk-Hordern. 
Wastewater analysis for drug usage estimation is a promising tool. However, this 
methodology will never be a stand-alone approach due to inherit limitations. Estimations 
through wastewater analysis cannot provide data with regards to the individuals taking the 
drugs; for example sex, age and ethnicity. Neither can data be provided on the dose, 
frequency or method of administration (although the method of administration may be 
determined for some compounds in which differentiating metabolites can be identified, e.g. 
cocaine snorting and smoking). In reality, it is likely that wastewater estimations will be 
complimentary to classical socio-epidemical studies, with wastewater analysis allowing 
authorities the important capacity to generate rapid drug estimates when required. 
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 Table 1 – Overview of parameters used in the sewage epidemiology calculations for each 
compound 
Compound DTR Stability 
(%)
a
 
Sorption to 
SPM (%)
b
 
% of dose excreted 
as DTR
c
 
Molar ratio 
parent/DTR 
Stimulants      
Cocaine Cocaine -7.7 1.4 1.53 1.00 
 Benzoylecgoni
ne 
5.5 
0.4 
30.07 1.05 
 Norbenzoylecg
onine 
3.5 
0.6 
0.95 1.10 
 Norcocaine -9.9 - 0.037 1.05 
(cocaine + ethanol) Cocaethylene -6.8 1.3 unknown 0.96 
(crack cocaine) Anhydroecg. 
M. E. 
19.8 
- 
0.19 1.67 
 Ecgonidine  30.8 - 2 1.98 
Amphetamine   Amphetamine   46.8 0.5 30 1.00 
Methamphetamine  Methamphetam
ine  
8.1 
0.6 
43 1.00 
Methcathinone Methcathinone -56.5 - 5.5 1.00 
BZP BZP 55.6 - 6.7 (rat) 1.00 
TFMPP TFMPP 23.5 - 0.7 (rat) 1.00 
      
Hallucinogens      
MDA  MDA  3.4 - high' 1.00 
MDMA MDMA 1.4 1.1 20.3 1.00 
MDEA MDEA -1.5 - 19 1.00 
MBDB MBDB -8.6 - unknown 1.00 
 BDB -20.5 - unknown 1.07 
Mescaline Mescaline -7.1 - 57.5 1.00 
LSD LSD -3.5 - 31.3 (monkey) 1.00 
 O-H-LSD -4.7 - unknown 0.00 
      
Opioids and morphine derivatives     
Heroin Heroin -79.4 - 0.025 1.00 
 Morphine 48.9 0.9 55.0 1.29 
 6-
acetylmorphine 
-12.0 - 0.50 1.13 
Codeine Codeine 12.4 1.0 63.8 1.00 
 Norcodeine 4.5 2.3 5.1 1.05 
Oxycodone Oxycodone 9.6 - 8.9 1.00 
 Oxymorphone 31.0 - 10.7 1.05 
Morphine Normorphine 4.3 1.2 5 1.05 
Dihydrocodeine Dihydrocodein
e 
-6.0 
1.0 
54.0 1.00 
Buprenorphine Buprenorphine -5.9 - 1.02 1.00 
 Norbuprenorph
ine 
-3.7 
- 
9.65 1.13 
Methadone Methadone -6.7 7.1 27.8 1.00 
 EDDP -12.8 8.1 24.6 1.06 
 EMDP -17.7 - 1 1.12 
Fentanyl Fentanyl -8.3 - 3.2 (intravenous)  1.00 
 Norfentanyl -13.5 - 40.5 (intravenous) 1.45 
Propoxyphene  Propoxyphene  -1.8 2.0 1.3 1.00 
 Norpropoxyph
ene 
64.0 
3.8 
15.4 1.04 
Tramadol Tramadol -11.0 1.0 31.9 1.00 
 Nortramadol -44.2 1.6 18.7 1.06 
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Benzodiazepines      
Temazepam Temazepam 19.4 - 74.5 1.00 
Diazepam  Diazepam  -3.0 - Trace 1.00 
 Nordiazepam  15.6 - Approx. 7 1.05 
 Oxazepam 2.4 5.4 33 0.99 
Nitrazepam Nitrazepam -61.9 - 1.2 1.00 
 7-
aminonitrazepa
m 
29.8 - 37.2 1.12 
Chlordiazepoxide Chlordiazepoxi
de 
-14.4 - 6.9 1.00 
      
Antidepressants       
Dosulepin Dosulepin -7.4 16.5 11.3 1.00 
Amitriptyline Amitriptyline 10.1 10.7 2 1.00 
 Nortriptyline -7.8 12.5 3 1.05 
Fluoxetine Fluoxetine 8.2 50.8 11 1.00 
 Norfluoxetine 1.9 61.5 7 1.05 
Venlafaxine Venlafaxine -20.5 0.4 5 1.00 
      
Dissociative anaesthetics     
Phencyclidine  Phencyclidine  -3.2 - 10 1.00 
Ketamine  Ketamine  -0.8 0.6 2.3 (intravenous) 1.00 
 Norketamine  -2.7 0.4 1.6 (intravenous) 1.06 
      
Other      
Methaqualone Methaqualone -2.7 - 0.2 1.00 
Sildenafil Sildenafil 11.5 10.3 0 1.00 
Ephedrine  Ephedrine  -40.4 0.3 NA NA 
Norephedrine Norephedrine -65.1 - NA NA 
Caffeine Caffeine 8.4 - 1 1.00 
1,7-
dimethylxanthine 
1,7-
dimethylxanthi
ne 
-15.3 - 4 1.08 
Nicotine Nicotine 3.8 - NA NA 
Cotinine Cotinine 56.5 - NA NA 
a Stability change in raw wastewater at 19 °C after 12 hours. See paper by (Baker and Kasprzyk-Hordern 2011a) for further information regarding 
stability studies 
b Average sorption to SPM in collected wastewater samples. See paper by (Baker and Kasprzyk-Hordern 2011b) for further information regarding 
SPM analysis 
c For further information regarding the excretion of each compound refer to Supplementary Material. Unless stated otherwise excretion data is derived 
from human studies with a relevant form of administration 
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Table 2 – Average load (g day−1) of target analytes in sample collected over a one week period, calculated using Eq. (1). 
Compound DTR loads  (g day
-1
 ± standard deviation) (n = 2) 
  
10th March 
Thursday 
11th March 
Friday 
12th March 
Saturday 
14th March 
Monday 
15th March 
Tuesday 
16th March 
Wednesday 
17th March 
Thursday 
Stimulants                                           
Cocaine 516 ± 2.1 510 ± 4.9 567 ± 0.3 670 ± 2.5 396 ± 6.6 450 ± 15 456 ± 9.7 
Benzoylecgonine 1213 ± 25 1182 ± 36 1310 ± 40 1721 ± 44 1084 ± 32 1108 ± 31 997 ± 10 
Norbenzoylecgonine 32.9 ± 0.1 38.5 ± 1.1 43.8 ± 0.1 61.5 ± 1.0 38.8 ± 0.6 35.1 ± 0.9 30.8 ± 1.4 
Norcocaine -   - -   - -   - -   - -   - -   - -   - 
Cocaethylene 21.7 ± 0.1 22.3 ± 0.3 30.2 ± 0.3 57.0 ± 1.3 24.7 ± 0.7 18.8 ± 0.5 18.5 ± 0.6 
Anhydroecgonine 
methyl ester 
-   - -   - -   - -   - -   - -   - -   - 
Ecgonidine  -   - -   - -   - -   - -   - -   - -   - 
Amphetamine   108 ± 19 101 ± 2.0 71.9 ± 0.4 104 ± 3.9 61.2 ± 1.7 79.3 ± 0.6 87.1 ± 2.3 
Methamphetamine  25.2 ± 1.9 22.9 ± 0.0 20.7 ± 0.5 43.5 ± 1.4 21.2 ± 0.4 21.9 ± 0.7 19.4 ± 1.1 
Methcathinone -   - -   - -   - -   - -   - -   - -   - 
BZP -   - -   - -   - -   - -   - -   - -   - 
TFMPP -   - -   - 1.1 ± 0.0 2.3 ± 0.3 -   - 1.9 ± 0.1 -   - 
                                            
Hallucinogens                                           
MDA  -   - -   - -   - 20.0 ± 0.9 -   - -   - -   - 
MDMA 55.2 ± 2.2 48.4 ± 0.9 62.6 ± 2.2 270 ± 8.7 107 ± 3.7 112 ± 3.0 59.1 ± 0.7 
MDEA -   - -   - -   - -   - -   - -   - -   - 
MBDB -   - -   - -   - -   - -   - -   - -   - 
BDB -   - -   - -   - -   - -   - -   - -   - 
Mescaline -   - -   - -   - -   - -   - -   - -   - 
LSD -   - -   - -   - -   - -   - -   - -   - 
O-H-LSD -   - -   - -   - -   - -   - -   - -   - 
                                            
Opiods and morphine derivatives                                     
Heroin -   - -   - -   - -   - -   - -   - -   - 
6-acetylmorphine 7.3 ± 0.0 7.0 ± 0.3 19.5 ± 0.4 9.4 ± 0.4 4.0 ± 0.3 4.5 ± 0.0 15.4 ± 1.3 
Codeine 1199 ± 20 1220 ± 1.2 1346 ± 13 1159 ± 13 1239 ± 55 1270 ± 2.0 1129 ± 16 
Norcodeine 35.3 ± 1.9 39.9 ± 1.9 38.6 ± 3.4 37.3 ± 1.8 35.3 ± 1.9 36.7 ± 2.7 37.7 ± 1.4 
Oxycodone 5.4 ± 0.3 6.2 ± 1.1 5.8 ± 0.9 6.1 ± 0.5 -   - -   - -   - 
Oxymorphone -   - 10.7 ± 0.5 9.8 ± 0.4 9.6 ± 0.3 -   - 10.1 ± 1.7 9.5 ± 1.1 
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Morphine 275 ± 2.6 277 ± 16.2 315 ± 7.8 269 ± 14 284 ± 15 267 ± 16 290 ± 26 
Normorphine 67.4 ± 2.1 70.1 ± 6.7 74 ± 6.2 68.3 ± 5.5 77.8 ± 6.3 68.9 ± 2.0 57.5 ± 17 
Dihydrocodeine 457 ± 2.9 450 ± 2.5 479 ± 2.9 436 ± 1.5 429 ± 1.1 482 ± 14.2 410 ± 5.5 
Buprenorphine -   - -   - -   - -   - -   - -   - -   - 
Norbuprenorphine -   - -   - -   - -   - -   - -   - -   - 
Methadone 72.3 ± 1.0 76.1 ± 0.1 81.4 ± 0.6 76.9 ± 1.4 70.0 ± 0.7 77.2 ± 1.1 71.7 ± 1.2 
EDDP 112 ± 5.9 109 ± 1.8 116 ± 4.0 108 ± 2.3 103 ± 0.1 126 ± 1.1 111 ± 8.4 
EMDP -   - -   - -   - -   - -   - -   - -   - 
Fentanyl -   - -   - -   - -   - -   - -   - -   - 
Norfentanyl -   - -   - -   - -   - -   - -   - -   - 
Propoxyphene  -   - -   - -   - 17.2 ± 0.1 -   - -   - -   - 
Norpropoxyphene 116 ± 6.5 123 ± 2.1 129 ± 12 117 ± 13 135 ± 4.1 134 ± 5.2 123 ± 13 
Tramadol 1134 ± 17 1079 ± 14 1037 ± 16 976 ± 21 1080 ± 71 1100 ± 17 962 ± 50 
Nortramadol 491 ± 95 485 ± 64 487 ± 44 551 ± 53 517 ± 13 542 ± 57 560 ± 92 
                                            
Benzodiazepines                                           
Temazepam 203 ± 14 206 ± 1.8 183 ± 12 205 ± 24 171 ± 7.8 199 ± 15 162 ± 22 
Diazepam  -   - -   - -   - -   - -   - -   - -   - 
Nordiazepam  15.1 ± 3.5 16.6 ± 6.4 15.2 ± 3.7 12.1 ± 3.8 18.3 ± 6.8 16.8 ± 6.2 20.0 ± 12 
Nitrazepam -   - -   - -   - -   - -   - -   - -   - 
7-aminonitrazepam -   - -   - -   - -   - -   - -   - -   - 
Oxazepam 32.8 ± 1.0 31.5 ± 2.3 31.8 ± 1.9 29.9 ± 1.3 31.1 ± 0.3 33.6 ± 0.7 26.8 ± 2.0 
Chlordiazepoxide -   - -   - -   - -   - -   - -   - -   - 
                                            
Antidepressants                                            
Dosulepin 32.5 ± 1.1 43.5 ± 5.3 42.3 ± 3.9 43.1 ± 3.2 43.1 ± 6.6 49.0 ± 3.1 44.6 ± 8.3 
Amitriptyline 132 ± 4.7 159 ± 22 153 ± 29 126 ± 12 153 ± 33 167 ± 13 135 ± 30 
Nortriptyline 12.3 ± 1.1 10.8 ± 2.1 9.3 ± 2.0 7.4 ± 1.7 8.5 ± 2.7 11.3 ± 1.7 8.7 ± 2.7 
Fluoxetine 33.1 ± 1.7 38.8 ± 3.7 39.3 ± 1.1 30.4 ± 0.3 41.7 ± 4.8 42.3 ± 1.4 30.8 ± 3.5 
Norfluoxetine 11.7 ± 0.1 10.9 ± 3.3 9.8 ± 1.8 11.1 ± 4.6 15.6 ± 2.6 17.0 ± 0.8 9.9 ± 4.4 
Venlafaxine 241 ± 7.7 237 ± 4.0 200 ± 2.6 178 ± 1.0 179 ± 0.3 241 ± 4.9 242 ± 0.4 
                                            
Dissociative anaesthetics                                          
Phencyclidine  -   - -   - -   - -   - -   - -   - -   - 
Ketamine  176 ± 4.3 193 ± 1.4 245 ± 2.2 280 ± 4.2 262 ± 2.4 327 ± 1.4 179 ± 1.2 
Norketamine  31.1 ± 0.8 48.3 ± 0.5 66.2 ± 0.7 103 ± 3.1 47.7 ± 0.8 52.9 ± 0.5 42.5 ± 0.1 
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Other                                           
Methaqualone -   - -   - -   - -   - -   - -   - -   - 
Sildenafil 9.9 ± 0.3 12.9 ± 1.3 12.0 ± 1.4 15.0 ± 1.0 12.9 ± 2.3 14.0 ± 1.7 12.7 ± 1.1 
Ephedrine 1766 ± 9.6 1890 ± 91 1743 ± 23 1577 ± 5.0 1884 ± 39 1739 ± 26 1582 ± 44 
Norephedrine -   - -   - -   - -   - -   - -   - -   - 
Caffeine 27075 ± 934 26420 ± 380 24876 ± 279 22934 ± 483 22082 ± 258 26929 ± 105 26200 ± 628 
1,7-dimethylxanthine 26026 ± 357 25737 ± 106 22747 ± 53 21992 ± 201 21633 ± 92 25544 ± 882 24966 ± 1187 
Nicotine 8731 ± 31.2 9061 ± 122 9402 ± 391 10936 ± 142 8094 ± 117 9392 ± 191 8132 ± 111 
Continine -   - -   - -   - -   - -   - -   - -   - 
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Table 3 – Wastewater derived drug consumption estimates, calculated using Eq. (2). 
Compound 
DTR Loads  (mg day
-1 1000 people-1 ± standard deviation) (n = 2) 
 
  
10th March 
Thursday 
11th March 
Friday 
12th March 
Saturday 
14th March 
Monday 
15th March 
Tuesday 
16th March 
Wednesday 
17th March 
Thursday 
Stimulants                                           
Cocaine Cocaine 9922 ± 41 9810 ± 94 10903 ± 4.9 12876 ± 47 7621 ± 127 8645 ± 283 8773 ± 187 
 Benzoylecgonine 1245 ± 26 1213 ± 37 1344 ± 41 1767 ± 45 1112 ± 33 1138 ± 32 1023 ± 11 
 Norbenzoylecgonine 1120 ± 3.6 1310 ± 38 1491 ± 4.3 2093 ± 35 1321 ± 21 1195 ± 31 1048 ± 49 
 Norcocaine ND     ND     ND     ND     ND     ND     ND     
 Cocaethylene n/a     n/a     n/a     n/a     n/a     n/a     n/a     
 Anhydroecgonine 
methyl ester 
ND     ND     ND     ND     ND     ND     ND     
 Ecgonidine  ND     ND     ND     ND     ND     ND     ND     
Amphetamine Amphetamine   105 ± 18 98.8 ± 2.0 70.4 ± 0.4 102.0 ± 3.8 60.0 ± 1.6 77.7 ± 0.6 85.3 ± 2.2 
Methamphetamine Methamphetamine  17.3 ± 1.3 15.7 ± 0.0 14.2 ± 0.4 29.8 ± 0.9 14.5 ± 0.3 15.0 ± 0.5 13.3 ± 0.8 
Methcathinone Methcathinone ND     ND     ND     ND     ND     ND     ND     
BZP BZP ND     ND     ND     ND     ND     ND     ND     
TFMPP TFMPP ND     ND     45.9 ± 0.6 95.9 ± 10.7 ND     81.7 ± 2.4 ND     
                                             
Hallucinogens                                           
MDA  MDA  n/a     n/a     n/a     n/a     n/a     n/a     n/a     
MDMA MDMA 80.1 ± 3.3 70.2 ± 1.4 90.8 ± 3.1 392 ± 12.6 155 ± 5.4 163 ± 4.3 85.7 ± 1.0 
MDEA MDEA ND     ND     ND     ND     ND     ND     ND     
MBDB MBDB n/a     n/a     n/a     n/a     n/a     n/a     n/a     
 BDB n/a     n/a     n/a     n/a     n/a     n/a     n/a     
Mescaline Mescaline ND     ND     ND     ND     ND     ND     ND     
LSD LSD ND     ND     ND     ND     ND     ND     ND     
 O-H-LSD n/a     n/a     n/a     n/a     n/a     n/a     n/a     
                       
Opiods and morphine derivatives                                           
Heroin Heroin ND     ND     ND     ND     ND     ND     ND     
 6-acetylmorphine 487 ± 1.0 466 ± 19 1297 ± 25 623 ± 27 264 ± 18 302 ± 0.9 1025 ± 84 
Codeine Codeine 554 ± 9.0 563 ± 0.6 622 ± 6.2 535 ± 5.8 572 ± 25 587 ± 0.9 521 ± 7.2 
 Norcodeine 213 ± 11 241 ± 12 234 ± 21 226 ± 11 214 ± 12 222 ± 17 228 ± 8.5 
Oxycodone Oxycodone 18.0 ± 0.8 20.3 ± 3.5 19.1 ± 2.9 20.2 ± 1.5 ND     ND     ND     
 Oxymorphone ND     30.9 ± 1.4 28.3 ± 1.1 27.6 ± 0.8 ND     28.9 ± 4.8 27.2 ± 3.0 
Morphine Morphine n/a     n/a     n/a     n/a     n/a     n/a     n/a     
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 Normorphine 417 ± 13 434 ± 42 455 ± 38 422 ± 34 481 ± 39 426 ± 13 355 ± 106 
Dihydrocodeine Dihydrocodeine 249 ± 1.6 245 ± 1.3 261 ± 1.6 237 ± 0.8 233 ± 0.6 262 ± 7.7 223 ± 3.0 
Buprenorphine Buprenorphine ND     ND     ND     ND     ND     ND     ND     
 Norbuprenorphine ND     ND     ND     ND     ND     ND     ND     
Methadone Methadone 80.5 ± 1.1 84.7 ± 0.1 90.7 ± 0.6 85.7 ± 1.5 78.0 ± 0.8 86.1 ± 1.3 79.9 ± 1.3 
 EDDP 113 ± 6.0 110 ± 1.8 118 ± 4.0 109 ± 2.4 104 ± 0.1 127 ± 1.1 112 ± 8.5 
 EMDP ND     ND     ND     ND     ND     ND     ND     
Fentanyl Fentanyl ND     ND     ND     ND     ND     ND     ND     
 Norfentanyl ND     ND     ND     ND     ND     ND     ND     
Propoxyphene Propoxyphene  ND     ND     ND     389 ± 2.4 ND     ND     ND     
 Norpropoxyphene 230 ± 13 245 ± 4.2 256 ± 23 232 ± 26 268 ± 8.1 267 ± 10 246 ± 26 
Tramadol Tramadol 1150 ± 18 1095 ± 14 1052 ± 17 990 ± 22 1095 ± 72 1115 ± 17 976 ± 51 
 Nortramadol 897 ± 173 885 ± 118 890 ± 80 1007 ± 96 945 ± 23 991 ± 103 1023 ± 168 
                                             
Benzodiazepines                                           
Temazepam Temazepam 79.9 ± 5.6 81.0 ± 0.7 72.3 ± 4.8 80.8 ± 9.4 67.4 ± 3.1 78.3 ± 5.7 63.9 ± 8.8 
Diazepam  Diazepam  n/a     n/a     n/a     n/a     n/a     n/a     n/a     
 Nordiazepam  66.6 ± 16 73.1 ± 28 67.0 ± 16 53.4 ± 17 80.7 ± 30 74.0 ± 27 88.5 ± 52 
Nitrazepam Nitrazepam ND     ND     ND     ND     ND     ND     ND     
 7-aminonitrazepam ND     ND     ND     ND     ND     ND     ND     
Oxazepam Oxazepam 29.0 ± 0.9 27.9 ± 2.0 28.1 ± 1.6 26.5 ± 1.1 27.5 ± 0.3 29.7 ± 0.6 23.7 ± 1.7 
Chlordiazepoxide Chlordiazepoxide ND     ND     ND     ND     ND     ND     ND     
                                             
Antidepressants                                            
Dosulepin Dosulepin 84.6 ± 2.8 113.2 ± 13.7 110 ± 10.3 112 ± 8.3 112 ± 17 126 ± 8.2 116 ± 22 
Amitriptyline Amitriptyline 1935 ± 69 2342 ± 320 2253 ± 424 1855 ± 521 2245 ± 481 2455 ± 197 1990 ± 434 
 Nortriptyline 127 ± 12 111 ± 22 96.0 ± 20 76.6 ± 18 88.0 ± 27 117 ± 18 89.6 ± 27.4 
Fluoxetine Fluoxetine 88.4 ± 4.5 104 ± 10 105 ± 2.8 81.4 ± 0.9 112 ± 13 113 ± 3.7 82.3 ± 9.3 
 Norfluoxetine 51.3 ± 0.4 48.2 ± 14 43.2 ± 7.9 48.7 ± 20 68.8 ± 12 74.7 ± 3.6 43.5 ± 19 
Venlafaxine Venlafaxine 1419 ± 45 1396 ± 23 1176 ± 15 1045 ± 5.9 1055 ± 1.6 1418 ± 29 1423 ± 2.2 
                                             
Dissociative anaesthetics                                           
Phencyclidine  Phencyclidine  ND     ND     ND     ND     ND     ND     ND     
Ketamine  Ketamine  n/a     n/a     n/a     n/a     n/a     n/a     n/a     
 Norketamine  n/a     n/a     n/a     n/a     n/a     n/a     n/a     
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Other                                           
Methaqualone Methaqualone ND     ND     ND     ND     ND     ND     ND     
Sildenafil Sildenafil n/a     n/a     n/a     n/a     n/a     n/a     n/a     
Ephedrine Ephedrine n/a     n/a     n/a     n/a     n/a     n/a     n/a     
 Norephedrine n/a     n/a     n/a     n/a     n/a     n/a     n/a     
Caffeine Caffeine 796318.7 ± 27459.6 777042.9 ± 11171.7 731633.2 ± 8216.4 674522.0 ± 14215.4 649454.8 ± 7593.4 792018.6 ± 3082.6 770600.7 ± 18469.7 
 1,7-dimethylxanthine 206231.3 ± 2824.9 203942.5 ± 843.1 180253.4 ± 418.5 174266.4 ± 1593.9 171421.2 ± 726.7 202418.4 ± 6988.3 197832.7 ± 9410.7 
Nicotine Nicotine n/a     n/a     n/a     n/a     n/a     n/a     n/a     
 Continine n/a     n/a     n/a     n/a     n/a     n/a     n/a     
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Table 4 – Consumption of legal drugs using wastewater results and NHS data 
 
 
 
Compound DTR Consumption estimates in local communities (mg 
day
-1
 1000 people
-1
) 
NHS data (2010) Wastewater analysis (2010) 
Opioids and morphine derivatives   
Codeine Codeine 1946 565 
 Norcodeine  225 
    
Oxycodone Oxycodone 54 20 
 Oxymorphone  29 
    
Dihydrocodeine Dihydrocodeine 225 244 
    
Methadone Methadone 97 84 
 EDDP  113 
    
Propoxyphene  Norpropoxyphe. 47 249 
    
Tramadol Tramadol 1654 1068 
    
Benzodiazepines    
Temazepam Temazepam 54 75 
    
Diazepam  Oxazepam 37 28 
    
Antidepressants     
Dosulepin Dosulepin 191 111 
    
Amitriptyline Amitryptyline 419 2154 
 Nortriptyline  101 
    
Fluoxetine Fluoxetine 226 98 
 Norfluoxetine  54 
    
Venlafaxine Venlafaxine 417 1276 
